AN2 Therapeutics
Agent32Agent Readiness: 32/100. Below median. Measured by StartupHub.ai. Median 41.Clinical-stage biopharmaceutical company developing novel boron-based small molecule therapeutics for rare infectious diseases and oncology.
About
AN2 Therapeutics is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, melioidosis, and NTM lung disease caused by M. abscessus, along with programs focused on targets in oncology and infectious diseases.
Key facts
At-a-glance profile data
- Website
- an2therapeutics.com
- Headquarters
- Menlo Park, United States
- Founded
- 2018
- Total funding
- $132M (Private Placement)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 9 Mar 2026 | Private Placement | $40M | - |
| 7 Jan 2022 | Series B | $80M | - |
| 21 Nov 2019 | Series A | $12M | - |
Tech stack
Detected on an2therapeutics.com, last scanned 16 Aug 2026. Run your own scan
- Frontend
- jQuery
- Analytics
- Google Analytics 4
- Hosting
- AWS
Frequently asked
What does AN2 Therapeutics do?
They are committed to delivering high-impact drugs to patients that address critical unmet needs and improve health outcomes.
How much funding has AN2 Therapeutics raised?
AN2 Therapeutics has raised a total of $132M in funding. The most recent round on record is Private Placement.